Arcturus Therapeutics Holdings Inc
ARCT
查看详细走势图
6.860USD
-0.220-3.11%
交易中 （美东）报价延迟15分钟
7.64M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.11%
5天
+3.47%
1月
-16.65%
6月
-63.47%
今年开始到现在
+11.91%
1年
-40.76%
查看详细走势图
TradingKey Arcturus Therapeutics Holdings Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
Arcturus Therapeutics Holdings Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名92/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价25.27。中期看，股价处于平稳状态。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Arcturus Therapeutics Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Arcturus Therapeutics Holdings Inc亮点
亮点风险
Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
业绩增长期
公司处于发展阶段，最新年度总收入82.03M美元
利润高增长
公司净利润处于行业前列，最新年度总收入82.03M美元
估值合理
公司最新PE估值-2.81，处于3年历史合理位
机构加仓
最新机构持股24.41M股，环比增加0.27%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值14.26K
活跃度增加
近期活跃度增加，过去20天平均换手率0.56
分析师目标
根据
13
位分析师
买入
评级
25.273
目标均价
+256.96%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Arcturus Therapeutics Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Arcturus Therapeutics Holdings Inc简介
Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
公司代码ARCT
公司Arcturus Therapeutics Holdings Inc
CEOPayne (Joseph E)
网址https://arcturusrx.com/
相关品种
